Feringa H H H, Bax J J, Poldermans D
Afd. Cardiologie, Erasmus MC-Centrum, Dr.Molewaterplein 40, 3015 GD Rotterdam.
Ned Tijdschr Geneeskd. 2008 Nov 29;152(48):2606-11.
Cardiovascular complications are the leading cause of death after noncardiac surgery. Preoperative identification of patients with underlying coronary artery disease is important, and appropriate treatment strategies should be implemented in these patients in order to reduce the risk of perioperative complications. Based on recent findings, preoperative risk stratification models have been developed to identify high-, intermediate- or low-risk patients; the concentration of natriuretic peptides is a promising new preoperative risk marker. beta-blockers considerably reduce this risk. In clinical practice, important factors are adequate beta-blocker dosage, tight perioperative heart-rate control and continuation of beta-blockers after discharge. Recently, statins have emerged as drugs with perioperative cardioprotective properties, but more randomized clinical trials are needed before routine administration ofstatins can be recommended. Perioperative medical management should focus on improvements not only in the short-term but also in the long-term.
心血管并发症是非心脏手术后的主要死亡原因。术前识别潜在冠状动脉疾病患者很重要,应在这些患者中实施适当的治疗策略,以降低围手术期并发症的风险。基于最近的研究结果,已开发出术前风险分层模型来识别高、中或低风险患者;利钠肽浓度是一种很有前景的新术前风险标志物。β受体阻滞剂可显著降低这种风险。在临床实践中,重要因素包括足够的β受体阻滞剂剂量、围手术期严格的心率控制以及出院后继续使用β受体阻滞剂。最近,他汀类药物已成为具有围手术期心脏保护特性的药物,但在推荐常规使用他汀类药物之前,还需要更多的随机临床试验。围手术期医疗管理不仅应注重短期改善,还应注重长期改善。